Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: Results of a double-blind, placebo-controlled trial

Schizophrenia Bulletin

Volumn 34, Issue 6, 2008, Pages 1172-1181

  Bergemann, Niels ^a   Parzer, Peter ^a   Jaggy, Susanne ^a   Auler, Beatrice ^a   Mundt, Christoph ^a   Maier Braunleder, Sabine ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Concrete thinking; Concretism; Estrogen; Formal thought disorder; Language disturbances; Metaphoric speech; Schizophrenia; Verbal ability; Women; Word fluency

Indexed keywords

CLOZAPINE; ESTRADIOL; ESTRIFAM; ESTROGEN; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NORETHISTERONE ACETATE; PERPHENAZINE; PLACEBO; RISPERIDONE; SERTINDOLE; TRISEQUENS; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPREHENSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTEGRATION; LANGUAGE DISABILITY; MALE; MENTAL DISEASE; NEUROPHYSIOLOGY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SPEECH; THOUGHT DISORDER; TREATMENT DURATION; VERBAL COMMUNICATION;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BRIEF PSYCHIATRIC RATING SCALE; COMPREHENSION; CROSS-OVER STUDIES; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; METAPHOR; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NORETHINDRONE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SPEECH PERCEPTION; THINKING; VERBAL BEHAVIOR;

EID: 54249154625     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm138     Document Type: Article

References (103)

1. Hampson E. Sex differences in human brain and cognition: the influence of sex steroids in early and adult life. In: Becker JB, Breedlove SM, Crews D, McCarthy MM, eds. Behavioral Endocrinology. 2nd ed. Cambridge, Mass: MIT Press; 2002:579-628.
2. Halbreich U, Lumley LA. The multiple interactional biological processes that might lead to depression and gender differences in its appearance. J Affect Disord. 1993;29:159-173.
3. Sherwin BB. Estrogen and cognitive functioning in women. Proc Soc Exp Biol Med. 1998;217:17-22.
4. Fink G, Sumner BEH, McQueen JK, Wilson H, Rosie R. Sex steroids control of mood, mental state and memory. Clin Exp Pharmacol Physiol. 1998;25:764-775.
5. Norbury R, Craig M, Cutter WJ, Whitehead M, Murphy DGM. Oestrogen: brain ageing, cognition and neuropsychiatric disorder. J Br Menopause Soc. 2004;10:118-122.
6. Vedder H, Behl C. Estrogens in neuropsychiatric disorders: from physiology to pathophysiology. In: Bergemann N, Riecher-Rössler A, eds. Estrogen Effects in Psychiatric Disorders. New York, NY: Springer; 2005:1-30.
7. Hampson E. Spatial cognition in humans: possible modulation by androgens and estrogens. J Psychiatry Neurosci. 1995;20:397-404.
8. Kimura D. Sex and Cognition. Cambridge, Mass: MIT Press; 1999.
9. Halpern DF. Sex Differences in Cognitive Abilities. 3rd ed. Hillsdale, NJ: Erlbaum; 2000.
10. Kimura D, Clarke P. Womens's advantage on verbal memory is not restricted to concrete words. Psychol Rep. 2002;91:1137-1142.
11. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate ('Harmogen') and its effect on memory. Curr Med Res Opin. 1976;4:303-306.
12. Robinson D, Friedman L, Marcus R, Tinklenber J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 1994;42:919-922.
13. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979-983.
14. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 1997;49:1491-1497.
15. Carlson LE, Sherwin BB. Steroid hormones, memory and mood in a healthy elderly population. Psychoneuroendocrinology. 1998;23:583-603.
16. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.
17. Maki MP, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001;158:227-233.
18. Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy. Horm Behav. 2000;38:262-276.
19. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
20. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.
21. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 1996;81:2545-2549.
22. Haskell SG, Richardson ED, Horwitz RI. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol. 1997;50:1249-1264.
23. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci. 1999;24:315-321.
24. Sherwin BB. The clinical relevance of the relationship between estrogen and cognition in women. J Steroid Biochem Mol Biol. 2007;106:151-156.
25. Mayes JT, Jahoda G, Neilson I. Patterns of visual-spatial performance and 'spatial ability': dissociation of ethnic and sex differences. Br J Psychol. 1988;79:105-119.
26. Quaiser-Pohl C, Lehmann W. Girls' spatial abilities: charting the contributions of experiences and attitudes in different academic groups. Br J Educ Psychol. 2002;72:245-260.
27. Cherney ID, Jagarlamudi K, Lawrence E, Shimabuku N. Experiential factors in sex differences on mental rotation. Percept Mot Skills. 2003;96:1062-1070.
28. Devlin AS. Sailing experience and sex as correlates of spatial ability. Percept Mot Skills. 2004;98:1409-1421.
29. Levine SC, Vasilyeva M, Lourenco SF, Newcombe NS, Huttenlocher J. Socioeconomic status modifies the sex difference in spatial skill. Psychol Sci. 2005;16:841-845.
30. Ginn SR, Pickens SJ. Relationships between spatial activities and scores on the mental rotation test as a function of sex. Percept Mot Skills. 2005;100:877-881.
31. Contreras MJ, Rubio VJ, Peña D, Colom R, Santacreu J. Sex differences in dynamic spatial ability: the unsolved question of performance factors. Mem Cognit. 2007;35:297-303.
32. Perlick D, Mattis S, Stastny P, Teresi J. Gender differences in cognition in schizophrenia. Schizophr Res. 1992;8:69-73.
33. Goldberg TE, Gold JM, Torrey EP, Weinberger DR. Lack of sex differences in the neuropsychological performance of patients with schizophrenia. Am J Psychiatry. 1995;152:883-888.
34. Andia AM, Zisook S, Heaton RK, et al. Gender differences in schizophrenia. J Nerv Ment Dis. 1995;183:522-528.
35. Lewine RR, Walker EF, Shurett R, Caudle J, Haden C. Sex differences in neuropsychological functioning among schizophrenic patients. Am J Psychiatry. 1996;153:1178-1184.
36. Albus M, Hubmann W, Mohr F, et al. Are there gender differences in neuropsychological performance in patients with first-episode schizophrenia? Schizophr Res. 1997;28:39-50.
37. Seidman LJ, Goldstein JM, Goodman JM, Koren D, Turner W, Tsuang MT. Sex differences in olfactory identification and Wisconsin card sorting performance in schizophrenia. Biol Psychiatry. 1997;42:104-115.
38. Goldstein JM, Seidman LJ, Goodman JM, et al. Are there sex differences in neuropsychological functions among patients with schizophrenia? Am J Psychiatry. 1998;155:1358-1364.
39. Hoff AL, Wieneke M, Faustman WO, et al. Sex differences in neuropsychological functioning of first-episode and chronically ill schizophrenic patients. Am J Psychiatry. 1998;155:1437-1439.
40. Halari R, Kumari V, Mehrota R, Wheeler M, Hines M, Sharma T. The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia. J Psychopharmacol. 2004;18:366-374.
41. Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983;24:125-128.
42. Häfner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci. 1991;241:65-68.
43. Häfner H, Riecher-Rössler A, an der Heiden W, Maurer K, Fatkenheuer B, Loffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med. 1993;23:925-940.
44. Bergemann N, Parzer P, Nagl I, et al. Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Womens Ment Health. 2002;5:119-126.
45. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994;20:203-214.
46. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phase, and psychopathology in women suffering from schizophrenia. Psychol Med. 2007;37:1427-1436.
47. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry. 1994;36:137-139.
48. Chua WL, Izquierdo de Santiago A, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst Rev. 2005;4:CD004719.
49. Bergemann N, Mundt C, Parzer P, et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res. 2005;74:125-134.
50. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48:(suppl 7):8-15.
51. Stevens JR. Schizophrenia: reproductive hormones and the brain. Am J Psychiatry. 2002;159:713-719.
52. Bergemann N, Riecher-Rössler A, eds. Estrogen Effects in Psychiatric Disorders. New York, NY: Springer; 2005.
53. Mortimer AM. Relationship between estrogen and schizophrenia. Expert Rev Neurother. 2007;7:45-55.
54. Behl C, Widmann M, Trapp T, Holsboer F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995;216:473-482.
55. Lee SJ, McEwen BS. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol. 2001;41:569-591.
56. Crow TJ. Nuclear schizophrenia symptoms as a window on the relationship between thought and speech. Br J Psychiatry. 1998;173:303-309.
57. DeLisi LE. Speech disorder in schizophrenia: review of the literature and exploration of its relation to uniquely human capacity for language. Schizophr Bull. 2001;27:481-496.
58. Finckh J. Zur Frage der Intelligenzprüfung [Testing intelligence]. Zentralbl Nervenheilkd Psychiatr. 1906;29:945-957.
59. Vigotsky LS. Thought in schizophrenia. Arch Neurol Psychiatry. 1934;31:1063-1077.
60. Muncie W. The psychopathology of metaphor. Arch Neurol Psychiatry. 1937;37:796-804.
61. Goldstein K. Methodological approach to the study of schizophrenic thought disorder. In: Kasanin JS, ed. Language and Thought in Schizophrenia. Berkeley, Calif: University of California Press; 1944.
62. Chapman LJ. Confusion of figurative and literal usages of words by schizophrenics and brain damaged patients. J Abnorm Soc Psychol. 1960;60:412-416.
63. Spitzer M, Lukas M, Maier S, Hermle L. Das Verstehen metaphorischer Rede bei gesunden Probanden und schizophrenen Patienten [Comprehension of metaphoric speech by schizophrenic patients and healthy controls. An experimental contribution]. Nervenarzt. 1994;65:282-292.
64. Barth A, Küfferle B. Die Entwicklung eines Sprichworttests zur Erfassung konkretistischer Denkstörungen bei schizophrenen Patienten [A proverb test to evaluate concretistic thought disorders in schizophrenia]. Nervenarzt. 2001;72:853-858.
65. Kircher TTJ, Leube DT, Erb M, Grodd W, Rapp AM. Neural correlates of metaphor processing in schizophrenia. Neuroimage. 2007;34:281-289.
66. Langdon R, Coltheart M, Ward PB, Catts SV. Disturbed communication in schizophrenia: the role of poor pragmatics and poor mind-reading. Psychol Med. 2002;32:1273-1284.
67. Benjamin JD. A method for distinguishing and evaluating formal thinking disorders in schizophrenia. In: Kasanin JS, ed. Language and Thought in Schizophrenia. Berkeley, Calif: University of California Press; 1944.
68. Blaufarb H. A demonstration of verbal abstracting ability in chronic schizophrenics under enriched stimulus and instructional conditions. J Consult Psychol. 1962;26:471-475.
69. Holm-Hadulla R-M, Haug F. Die Interpretation von Sprichwörtern als klinische Methode zur Erfassung schizophrener Denk-, Sprach- und Symbolisationsstörungen [Interpretation of proverbs as a clinical method to exploring schizophrenic thought and speech disorders]. Nervenarzt. 1984;55:496-503.
70. Andreasen NC. Reliability and validity of proverb interpretation to assess mental status. Compr Psychiatry. 1977;18:465-472.
71. Gorham DR. A proverb test for clinical and experimental use. Psychol Rep. 1956;2:1-2.
72. Klinga K. Determination of hormones and hormone receptors. In: Runnebaum B, Rabe T, eds. Gynecological Endocrinology and Reproductive Medicine. Heidelberg, Germany: Springer; Vol. 1 (1997)45-54.
73. Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111:11-20.
74. Bergemann N, Mundt C, Parzer P, et al. Plasma concentration of estradiol in women suffering from schizophrenia treated with conventional and atypical antipsychotics. Schizophr Res. 2005;73:357-366.
75. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
76. Horn W. Leistungsprüfsystem L-P-S [Performance Test System]. Göttingen, Germany: Hogrefe; 1983.
77. Thurstone LL, Thurstone TG. Factorial Studies of Intelligence. Chicago , Ill: University of Chicago Press; 1941.
78. Conner CK. Continuous Performance Test - Version II. Tornoto, Canada: Multi Health System; 1992.
79. Stata Corporation. Stata Statistical Software: Release 9.2. College Station, Tex: Stata Corporation; 2005.
80. Rabe T, Runnebaum B. Hormones. In: Runnebaum B, Rabe T, eds. Gynecological Endocrinology and Reproductive Medicine. Heidelberg, Germany: Springer; Vol 1 1997:1-43.
81. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
82. Guy U ed. ECDEU Assessment Manual for Psychopharmacology. revised. DHEU Publication. Rockville, Md: National Institute of Mental Health; 1976: 76-338.
83. Beck AT, Steer RA. Beck Depression Inventory-Manual. San Antonio, Tex: The Psychological Corporation; 1987.
84. Hautzinger M, Bailer M, Worall H, Keller F. Beck-Depressions-Inventar (BDI), 2nd ed. Bern, Switzerland: Huber; 1995.
85. Thompson K, Sergejew A, Kulkarni J. Estrogen affects cognition in women with psychosis. Psychiatry Res. 2000;94:201-209.
86. Hoff AL, Kremen WS, Wieneke MH, et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry. 2001;158:1134-1139.
87. Ko Y-H, Joe S-H, Cho W, et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology. 2006;53:169-175.
88. Brekke JS, Hoe M, Long J, Green MF. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull. 2007;33:1247-1256.
89. Lysaker PH, Bell MD, Bioty SM. Cognitive deficits in schizophrenia. Prediction of symptom change for participators in work rehabilitation. J Nerv Ment Dis. 1995;183:332-336.
90. Heaton R, Chelune GT, Talley JL, Kay GG, Curtiss GG. Wisconsin Card Sorting Test Manual Revised and Expanded. Odessa, Fla: Psychological Assessment Resources, Inc; 1993.
91. Lysaker PH, Bell MD. Work rehabilitation and improvements in insight in schizophrenia. J Nerv Ment Dis. 1995;183:107.
92. Spaulding WD, Storms L, Goodrich V, Sullivan M. Applications of experimental psychopathology in psychiatric rehabilitation. Schizophr Bull. 1986;12:560-577.
93. Lysaker PH, Bell MD, Goulet JL. The Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatry Res. 1995;56:45-51.
94. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
95. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061-1071.
96. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428-436.
97. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314.
98. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80:1050-1057.
99. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
100. Shumaker SA, Legault C, Kuller L, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947-2958.
101. Schneider LS. Estrogen and dementia: insights from the Women's Health Initiative Memory Study. JAMA. 2004;291:3005-3007.
102. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy, physiological complexity belies therapeutic simplicity. Science. 2004;304:1269-1273.
103. Resnick SM, Maki PM, Rapp SR, et al. Women's Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802-1810.